Literature DB >> 28472551

Programmed death-ligand 1 immunohistochemistry testing for non-small cell lung cancer in practice.

Mari Mino-Kenudson1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28472551     DOI： 10.1002/cncy.21873

Source DB:  PubMed          Journal:  Cancer Cytopathol        ISSN： 1934-662X            Impact factor:   5.284


× No keyword cloud information.
  4 in total

1.  Implementation of PD-L1 22C3 IHC pharmDxTM in Cell Block Preparations of Lung Cancer: Concordance with Surgical Resections and Technical Validation of CytoLyt® Prefixation.

Authors:  Si Kei Lou; Hyang Mi Ko; Tomonari Kinoshita; Scott MacDonald; Jessica Weiss; Katarzyna Czarnecka-Kujawa; Scott L Boerner; Kazuhiro Yasufuku; Ming-Sound Tsao; Joerg Schwock
Journal:  Acta Cytol       Date:  2020-06-29       Impact factor: 2.319

Review 2.  Immunohistochemistry for predictive biomarkers in non-small cell lung cancer.

Authors:  Mari Mino-Kenudson
Journal:  Transl Lung Cancer Res       Date:  2017-10

3.  PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non-small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option?

Authors:  Vanda F Torous; Deepa Rangachari; Benjamin P Gallant; Meghan Shea; Daniel B Costa; Paul A VanderLaan
Journal:  J Am Soc Cytopathol       Date:  2018-02-16

4.  Histology versus cytology: PD-L1 testing in non-small cell lung cancer.

Authors:  Nagio Takigawa; Nobuaki Ochi; Hiromichi Yamane
Journal:  Transl Lung Cancer Res       Date:  2018-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.